Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors.

Boby ML. et al, (2023), Science, 382

Accelerating antiviral drug discovery: lessons from COVID-19.

von Delft A. et al, (2023), Nat Rev Drug Discov

Turning high-throughput structural biology into predictive inhibitor design.

Saar KL. et al, (2023), Proc Natl Acad Sci U S A, 120

Incoming HIV virion-derived Gag Spacer Peptide 2 (p1) is a target of effective CD8+ T cell antiviral responses.

Yang H. et al, (2021), Cell Rep, 35

Open Science Discovery of Potent Non-Covalent SARS-CoV-2 Main Protease Inhibitors

Boby ML. et al, (2020)

Viral vectored hepatitis C virus vaccines generate pan-genotypic T cell responses to conserved subdominant epitopes.

Donnison T. et al, (2020), Vaccine, 38, 5036 - 5048

MHC class II invariant chain-adjuvanted viral vectored vaccines enhances T cell responses in humans.

Esposito I. et al, (2020), Sci Transl Med, 12

The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes.

von Delft A. et al, (2018), Vaccine, 36, 313 - 321

Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus.

Ansari MA. et al, (2017), Nat Genet, 49, 666 - 673

Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection.

Swadling L. et al, (2016), Vaccines (Basel), 4

Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans.

Kelly C. et al, (2016), Hepatology, 63, 1455 - 1470

The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design.

von Delft A. et al, (2016), Gut, 65, 112 - 123

THE GENERATION OF AN IMMUNOGENIC SECOND-GENERATION CONSERVED SEGMENT HCV T CELLVACCINE TO TARGET MULTIPLE HCV GENOTYPES

Von Delft A. et al, (2016), JOURNAL OF HEPATOLOGY, 64, S506 - S506

Emergence of a distinct HIV-specific IL-10-producing CD8+ T-cell subset with immunomodulatory functions during chronic HIV-1 infection.

Clutton G. et al, (2013), Eur J Immunol, 43, 2875 - 2885

'Favourable' IL28B polymorphisms are associated with a marked increase in baseline viral load in hepatitis C virus subtype 3a infection and do not predict a sustained virological response after 24 weeks of therapy.

Bucci C. et al, (2013), J Gen Virol, 94, 1259 - 1265

Quantitative trait loci mapping of the mouse plasma proteome (pQTL).

Holdt LM. et al, (2013), Genetics, 193, 601 - 608

HCV genotype-3a T cell immunity: specificity, function and impact of therapy.

Humphreys IS. et al, (2012), Gut, 61, 1589 - 1599

Immune responses in acute and chronic HCV genotype 3a infection detected by two distinct techniques

von Delft A. et al, (2011), IMMUNOLOGY, 135, 66 - 66

Include forthcoming?